Business Context and Reporting Period
This Form 8-K, filed on May 29, 2020, by AcelRx Pharmaceuticals, Inc. (ACRX), reports the entry into Amendment No. 2 to the Merger Agreement with Tetraphase Pharmaceuticals, Inc. (Tetraphase) on May 29, 2020. The filing also details a revised Contingent Value Rights (CVR) Agreement and amendments to voting and co-promotion agreements. The transaction involves AcelRx acquiring Tetraphase, with Tetraphase continuing as a wholly-owned subsidiary.
Key Financial Metrics and Transaction Terms
The filing outlines the specific financial consideration for Tetraphase shareholders and contingent liabilities rather than standard operating metrics like revenue or profit, which are not provided in this document.
- Merger Consideration: Tetraphase shareholders will receive $0.5872 in cash per share, 0.7409 shares of AcelRx common stock per share, and one CVR.
- Cash Consideration Adjustment: The cash portion is reduced if Tetraphase's Net Cash is less than $5,000,000, potentially reducing the cash payment to $0.
- Exchange Ratio Adjustment: The stock exchange ratio is adjusted if Tetraphase's Net Cash is less than -$1,340,566.
- Termination Fee: Increased to $1,778,000 payable by Tetraphase under specified circumstances.
- Contingent Value Rights (CVRs): Total potential payout of up to $16.0 million based on XERAVA annual net sales milestones:
- $2.5 million for 2021 sales targets.
- $4.5 million for sales targets in any year through December 31, 2024.
- $9.0 million for sales targets in any year through December 31, 2024.
Material Changes Versus Prior Period
The filing represents a material amendment to the original Merger Agreement dated March 15, 2020, and a prior amendment dated May 27, 2020. Key changes include:
- Revised Consideration: Adjustments to the cash and stock exchange ratios based on Tetraphase's Net Cash position at closing.
- Increased Termination Fee: The fee payable by Tetraphase was raised to $1,778,000.
- Revised CVR Structure: The CVR agreement was updated to specify the $16.0 million aggregate potential payout structure tied to XERAVA sales.
- Rejection of Competing Bid: The Tetraphase board determined that a proposal from Melinta Therapeutics, Inc. received on May 27, 2020, was not superior to the amended AcelRx offer.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook: The Tetraphase board has approved the amended terms and recommends adoption by stockholders. The CVR terms reflect an agreement on sharing economic upside from XERAVA sales but do not represent anticipated sales figures.
Risks and Contingencies:
- Transaction Completion: Risks include the inability to close the acquisition, failure to achieve cost synergies, or delays caused by competing bidders or fluctuations in AcelRx's stock price.
- COVID-19 Impact: The ongoing pandemic may prolong or exacerbate operational impacts, addressed partially by a separate Co-Promotion Amendment regarding work level efforts.
- CVR Uncertainty: There is no assurance that XERAVA will achieve the sales levels required to trigger the $16.0 million in contingent payments.
- Forward-Looking Statements: The filing contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially.
Important Facts for Investor Verification
- Verify the definitive proxy statement/prospectus (Form S-4 No. 333-237584) for complete details on the transaction and voting procedures.
- Confirm Tetraphase's current Net Cash position to determine the final cash consideration and exchange ratio per share.
- Review the specific annual net sales thresholds for XERAVA required to trigger the $2.5 million, $4.5 million, and $9.0 million CVR payments.
- Assess the impact of the increased $1,778,000 termination fee on Tetraphase's liquidity if the deal fails.
- Monitor the status of the competing proposal from Melinta Therapeutics, Inc., which was deemed not superior but remains a market factor.